Table 2.
Patient Characteristics by Compliant Status
| 100% Compliant (N=1267) |
Non Compliant (N=373) |
Total (N=1640) |
P-value | |
|---|---|---|---|---|
| Age | 0.031 | |||
| Mean (SD) | 57.5 (9.5) | 58.6 (11.6) | 57.7 (10.0) | |
| Median | 57.0 | 59.0 | 58.0 | |
| Range | (24.0–95.0) | (26.0–86.0) | (24.0–95.0) | |
| Race | <0.012 | |||
| White | 1168 (92.2%) | 321 (86.1%) | 1489 (90.8%) | |
| Black or African American | 68 (5.4%) | 41 (11.0%) | 109 (6.6%) | |
| Native Hawaiian or Other Pacific Islander | 1 (0.1%) | 0 (0.0%) | 1 (0.1%) | |
| Asian | 15 (1.2%) | 4 (1.1%) | 19 (1.2%) | |
| American Indian or Alaska Native | 4 (0.3%) | 4 (1.1%) | 8 (0.5%) | |
| Not reported | 11 (0.9%) | 3 (0.8%) | 14 (0.9%) | |
| Gender | <0.012 | |||
| Female | 985 (77.7%) | 226 (60.6%) | 1211 (73.8%) | |
| Male | 281 (22.2%) | 147 (39.4%) | 428 (26.1%) | |
| Unknown | 1 (0.1%) | 0 (0.0%) | 1 (0.1%) | |
| ECOG Performance Status | <0.012 | |||
| Unknown | 32 | 6 | 38 | |
| 0 | 981 (79.4%) | 259 (70.6%) | 1240 (77.4%) | |
| 1–2 | 254 (20.6%) | 108 (29.4%) | 362 (22.6%) | |
| Tumor Status | 0.662 | |||
| Unknown | 1035 | 252 | 1287 | |
| Resected with no residual | 80 (34.5%) | 41 (33.9%) | 121 (34.3%) | |
| Resected with known residual | 32 (13.8%) | 12 (9.9%) | 44 (12.5%) | |
| Unresected | 109 (47.0%) | 60 (49.6%) | 169 (47.9%) | |
| Recurrent | 11 (4.7%) | 8 (6.6%) | 19 (5.4%) | |
| Cancer Type | <0.012 | |||
| Unknown | 1 (0.1%) | 0 (0.0%) | 1 (0.1%) | |
| Breast | 404 (31.9%) | 54 (14.5%) | 458 (27.9%) | |
| Breast/Gynecologic | 397 (31.3%) | 45 (12.1%) | 442 (27.0%) | |
| GI | 268 (21.2%) | 230 (61.7%) | 498 (30.4%) | |
| Gyn | 7 (0.6%) | 9 (2.4%) | 16 (1.0%) | |
| Head and Neck | 139 (11.0%) | 20 (5.4%) | 159 (9.7%) | |
| Heme | 5 (0.4%) | 1 (0.3%) | 6 (0.4%) | |
| Lung | 10 (0.8%) | 3 (0.8%) | 13 (0.8%) | |
| Prostate | 15 (1.2%) | 7 (1.9%) | 22 (1.3%) | |
| Other | 21 (1.7%) | 4 (1.1%) | 25 (1.5%) | |
| Clinical Stage | 0.812 | |||
| Unknown | 1194 | 366 | 1560 | |
| Stage I | 23 (31.5%) | 3 (42.9%) | 26 (32.5%) | |
| Stage II | 24 (32.9%) | 2 (28.6%) | 26 (32.5%) | |
| Stage III | 19 (26.0%) | 2 (28.6%) | 21 (26.3%) | |
| Other | 7 (9.6%) | 0 (0.0%) | 7 (8.8%) | |
| Length of Time on Study (in Days) | <0.011 | |||
| Mean (SD) | 95.0 (102.4) | 112.3 (86.9) | 98.9 (99.3) | |
| Median | 87.0 | 102.0 | 88.0 | |
| Range | (1.0–2079.0) | (2.0–1071.0) | (1.0–2079.0) | |
| Overall QOL | 0.423 | |||
| >=8 | 267 (21.1%) | 71 (19.0%) | 338 (20.6%) | |
| <8 | 1000 (78.9%) | 302 (81.0%) | 1302 (79.4%) | |
| Overall QOL | 0.123 | |||
| >=6 | 397 (31.3%) | 101 (27.1%) | 498 (30.4%) | |
| <6 | 870 (68.7%) | 272 (72.9%) | 1142 (69.6%) | |
| AE Grade >=3 (Y/N) | 0.363 | |||
| Not Collected | 395 | 65 | 460 | |
| N | 825 (94.6%) | 296 (96.1%) | 1121 (95.0%) | |
| Y | 47 (5.4%) | 12 (3.9%) | 59 (5.0%) | |
| AE Grade >=2 (Y/N) | 0.333 | |||
| Not Collected | 395 | 65 | 460 | |
| N | 698 (80.0%) | 238 (77.3%) | 936 (79.3%) | |
| Y | 174 (20.0%) | 70 (22.7%) | 244 (20.7%) | |
| Dose Reduced (Y/N) | <0.013 | |||
| Y | 43 (3.4%) | 34 (9.1%) | 77 (4.7%) | |
| N | 1224 (96.6%) | 339 (90.9%) | 1563 (95.3%) | |
| Dose Delayed (Y/N) | <0.013 | |||
| Y | 263 (20.8%) | 132 (35.4%) | 395 (24.1%) | |
| N | 1004 (79.2%) | 241 (64.6%) | 1245 (75.9%) | |
| Study Type | <0.012 | |||
| Cancer Control | 1208 (95.3%) | 331 (88.7%) | 1539 (93.8%) | |
| QOL | 11 (0.9%) | 1 (0.3%) | 12 (0.7%) | |
| Treatment Trial | 48 (3.8%) | 41 (11.0%) | 89 (5.4%) | |
1
Kruskal Wallis
2
Chi-Square
3
Fisher Exact